Sight Sciences Wins $34M in Patent Lawsuit Against Alcon

Edgen Stock

·Mar 30 2026, 11:21

Share to

Share to

Copy link

Key Takeaways

A court has finalized a jury verdict against Alcon, confirming willful patent infringement and awarding Sight Sciences significant financial compensation. The ruling includes over $34 million in past damages and future royalties, setting a major precedent in the glaucoma device market.

Court Upholds Verdict: A federal judge preserved a jury's finding that Alcon willfully infringed on Sight Sciences' patents for its Hydrus® Microstent.
Financial Award: Sight Sciences will receive over $34 million in past damages and ongoing royalties from Alcon through November 2028.
Market Impact: The decision creates a significant financial liability for Alcon and a new revenue stream for Sight Sciences, affecting both companies in the micro-invasive glaucoma surgery (MIGS) market.

Court Awards Sight Sciences Over $34M in Damages

A U.S. court has ordered Alcon to pay Sight Sciences more than $34 million, upholding a jury's verdict that Alcon willfully infringed on patents related to its Hydrus® Microstent. The ruling, announced on March 30, 2026, solidifies a significant legal and financial victory for Sight Sciences in the competitive micro-invasive glaucoma surgery (MIGS) device market.

The court's decision preserves the jury’s original finding and quantifies the past damages owed. This concludes a critical phase of the patent dispute, shifting the financial burden decisively onto Alcon for its use of the contested technology.

Alcon Faces Ongoing Royalties Through November 2028

Beyond the immediate one-time payment, the court order establishes an ongoing financial obligation for Alcon. The company is now required to pay royalties to Sight Sciences for sales related to the Hydrus Microstent until the patent's expiration in November 2028. This arrangement creates a new, predictable revenue stream for Sight Sciences (SGHT) and a recurring cost for Alcon (ALC).

For investors, this ruling positions Sight Sciences with a stronger balance sheet and a validated intellectual property portfolio. Conversely, Alcon faces not only the immediate multi-million dollar damage award but also sustained margin pressure on a key product for several years. The outcome is expected to directly influence investor sentiment and the competitive landscape for medical devices used in glaucoma treatment.